Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade
serous ovarian cancer: basic sciences, clinical and therapeutic
standpoints. Int...
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring
and comparing adverse events between PARP inhibitors.
Lancet Oncol. 2019;20(1):e15–e28....
O’Cearbhaill RE. Using PARP inhibitors in advanced ovarian
cancer running head: PARP inhibitors in ovarian cancer.
Oncology (Williston Park)....
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in
ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):
17–38. https://doi.org/10.1007/s00280-017-3501-8.
McFarlane T, Rehman N, Wang K, Lee J, Carter C. Cutaneous
toxicities of new targeted cancer therapies: must know for
diagnosis, management,...
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance
treatment for recurrent ovarian carcinoma after response to
platinum therapy (ARIEL3):...
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic
breast cancer in patients with a germline BRCA mutation.
N Engl J Med. 2017;377(6):523–533....
Wheelden M, Cream L, Sivik J, Robson M. A novel adverse
event associated with olaparib therapy in a patient with
metastatic breast cancer....
Mirza MR, Matulonis U. [Consultado 21 Mar 2020]. Disponible
en: https://clinicaltrials.gov/ct2/show/results/NCT01847274?
id=NCT01847274&draw=2&rank=1&load=cart.
Merk HF, Vanstreels L, Megahed M. Lichenoide
arzneimittelreaktionen. Der Hautarzt. 2018;69(2):116–120.
https://doi.org/10.1007/s00105-017-4117-y
